October 1, 2022 10:22 AM EDTUpdated October 3, 07:30 AM

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

Kyle LaHucik

Senior Reporter

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?